Abstract
Afatinib (BIBW 2992, US: Gilotrif™, other countries: Giotrif©) is an irreversible blocker of the ErbB family, acting at the tyrosine kinases of these proteins. In 2013, it was approved by the FDA and the EMA for the treatment of adults with advanced, EGFR mutation-positive non-small-cell lung cancer. Further investigations for the treatment of many other tumors with afatinib, e.g., HNSCC and breast cancer, are ongoing.
Author supplied keywords
Cite
CITATION STYLE
APA
Wecker, H., & Waller, C. F. (2018). Afatinib. In Recent Results in Cancer Research (Vol. 211, pp. 199–215). Springer New York LLC. https://doi.org/10.1007/978-3-319-91442-8_14
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free